How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?

Aza/ven patients had better EFS/QoL with a greater proportion of patients who successfully got to a stem cell transplant. Provided that the OS data is yet to mature, do these results change your current clinical practice?

Answer from: at Academic Institution

It was very exciting to see PARADIGM presented as a plenary at ASH, and I look forward to the manuscript! Interpreting the findings in the context of the enrolled patients is very important. The median age of enrolled patients was approximately 65 years in both arms, and ~75% of enrolled patients ha...

Comments

at Harvard Medical School
Agree with this nuanced response and similarly awa...

Please select the option that best describes you:

How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?

Related Questions